Here's Why It's Unlikely That Repligen Corporation's (NASDAQ:RGEN) CEO Will See A Pay Rise This Year

Key Insights Repligen's Annual General Meeting to take place on 16th of May Salary of US$880.0k is part of CEO Tony Hunt's total remuneration Total compensation is 35% above industry average Rep

Simply Wall StMay 10 05:34

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the

GlobeNewswireMay 7 06:30

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)

TipRanksMay 3 06:42

Repligen Is Maintained at Overweight by JP Morgan

Repligen Is Maintained at Overweight by JP Morgan

Dow JonesMay 2 11:55

JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 to $200.

BenzingaMay 2 11:45

Repligen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 24.86% JP Morgan $230 → $200 Maintains Overweight 02/22/2024 29.23% Stifel $165 → $207 Maintain

BenzingaMay 2 11:44